Zdrowie i gospodarka · 17/07/1996

Behring Diagnostics, Inc.; Premarket Approval of MicroTrak II IgM Anti-HAV EIA

The Food and Drug Administration (FDA) is announcing its approval of the application by Behring Diagnostics Inc., San Jose, CA, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of the MicroTrak II IgM Anti-HAV EIA. FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of May 13, 1996, of the approval of the application.